Table 1 Antimicrobial activity of test samples (N1, N2, N3) and standard compounds (Inhibition zone Diameter, Mean ± SD, mm).

From: In vitro, in silico, and DFT evaluation of antimicrobial imidazole derivatives with insights into mechanism of action

Sample

Conc. (µg/ml)

S.aureus (mm)

E.coli (mm)

P.aeruginosa (mm)

B.anthracoides (mm)

K.pneumoniae (mm)

C.albicans (mm)

N1

50

22 ± 1

18 ± 2

21 ± 1

20 ± 1

23 ± 1

27.9 ± 0.9

100

26 ± 1

22 ± 1

23.5 ± 0.7

22.0 ± 0.8

26.8 ± 0.8

30 ± 1

N2

50

26.5 ± 0.8

19 ± 2

22 ± 1

21.3 ± 0.5

25.6 ± 0.7

30.0 ± 0.4

100

29.3 ± 0.8

22.7 ± 0.8

25 ± 1

26 ± 2

28.4 ± 0.6

32 ± 0.3

N3

50

21 ± 1

9.3 ± 0.7

17 ± 1

18 ± 2

18.7 ± 0.8

26 ± 1

100

25 ± 1

12.2 ± 0.8

21 ± 1

21 ± 1

21 ± 1

29.1 ± 0.7

Cipro.

50

29 ± 1

27.5 ± 0.4

-

-

29 ± 1

-

100

30 ± 1

29.1 ± 0.4

-

-

30 ± 1

-

Fluco.

50

-

-

-

-

-

31.2 ± 0.7

100

-

-

-

-

-

31.8 ± 0.5

  1. Cipro Ciprofloxacin, Fluco Fluconazole, - standard compounds, Conc Concentration